A four-arm hormone trial can reveal a pattern of effects that a single “anti-aging” label obscures. This study assessed healthy community-dwelling older men. Primary report
Trial snapshot
Eighty men aged 65–80 entered a six-month randomized, double-blind study of GH, testosterone, their combination, or placebo. Some body-composition outcomes improved with GH-containing treatment. Aerobic capacity improved with the combination, but only one of six strength measures significantly increased in that group. GH alone was associated with increased bodily pain on the generic health questionnaire. Primary report
Our appraisal: count outcomes, not just favorable sentences
A broad list of measurements creates opportunities for selective emphasis. The reader should see which outcomes changed, which did not, and which moved unfavorably. Reporting only lean mass would omit the separate questions of strength, symptoms, and daily function.
Combination findings also need correct attribution. An advantage in a combined-treatment arm does not show that either component alone causes the same effect. To call an interaction synergistic, the analysis must test an interaction; two favorable observations are not enough.
Quality-of-life instruments can measure different constructs. A condition-specific questionnaire and a generic bodily-pain scale need not agree. Their divergence should be explained rather than resolved by choosing the preferred score.
The study population was not a universal sample of older adults or people with diagnosed GH deficiency. A modest six-month trial also cannot resolve uncommon or long-latency harms. Full review should inspect the endpoint hierarchy, multiplicity handling, withdrawals, and adverse-event tables. The useful result is the mixed outcome profile, not an endorsement of hormone use for ordinary aging.
Frequently asked questions
How many treatment groups were studied?
Four.
Were all strength measures improved?
No.
Was body composition the same outcome as strength?
No.
Was a pain signal reported?
Yes, with GH alone on the cited questionnaire.
Does a combination result prove synergy?
Not without an appropriate interaction analysis.
Does this establish long-term safety?
No.
What should readers retain?
The outcome-by-outcome pattern and the study population.